Surmodics (SRDX)
(Delayed Data from NSDQ)
$41.80 USD
+0.02 (0.05%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $41.84 +0.04 (0.10%) 7:58 PM ET
1-Strong Buy of 5 1
D Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$41.80 USD
+0.02 (0.05%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $41.84 +0.04 (0.10%) 7:58 PM ET
1-Strong Buy of 5 1
D Value F Growth C Momentum F VGM
Zacks News
Here's Why You Should Hold on to ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about ResMed (RMD) on its focus on digital health technology and robust demand for its critical care products.
Organigram (OGI) Catches Eye: Stock Jumps 11.7%
by Zacks Equity Research
Organigram (OGI) saw a big move last session, as its shares jumped nearly 12% on the day, amid huge volumes.
Myriad's (MYGN) EndoPredict Grows Amid Coronavirus Mayhem
by Zacks Equity Research
Within Molecular Diagnostics, Myriad Genetics (MYGN) registers strong sales for EndoPredict, myChoice CDx and BRACAnalysis CDx.
Hologic's Second Molecular Test Gets EUA to Detect Coronavirus
by Zacks Equity Research
Hologic (HOLX) expects to boost testing capacity by combining its manufacturing ability for the latest EUA of test with its largest installed base of high-throughput molecular instruments.
Surmodics (SRDX) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Surmodics (SRDX) registered growth in one of its core units, Invitro Diagnostics, in Q2.
SurModics (SRDX) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
SurModics (SRDX) delivered earnings and revenue surprises of 180.00% and 1.57%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain Inogen (INGN) Stock for Now
by Zacks Equity Research
Investor confidence is high on Inogen (INGN) stock, thanks to solid prospects.
AMN Healthcare Inks Deal to Address Healthcare System Needs
by Zacks Equity Research
This partnership is expected to boost AMN Healthcare's (AMN) Other Workforce Solutions segment.
Earnings Preview: SurModics (SRDX) Q2 Earnings Expected to Decline
by Zacks Equity Research
SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pacific Biosciences' Sequel II Gets Acquired by inqaba biotec
by Zacks Equity Research
Pacific Biosciences' (PACB) new development is likely to boost the company's flagship platform, the Sequel system.
Here's Why You Should Retain Accuray in Your Portfolio
by Sriparna Ghosal
Investor confidence remains high in Accuray (ARAY) stock, thanks to solid prospects.
Here's Why You Should Retain OPKO Health in Your Portfolio
by Zacks Equity Research
Investor confidence remains high in OPKO Health's (OPK) stock, thanks to solid prospects.
Amedisys Gains on Expanding Hospice Arm, Favorable Demography
by Zacks Equity Research
Amedisys' (AMED) recent acquisitions in the Hospice arm aid the company's growth.
Intersect Posts Preliminary Q1 Results, Withdraws '20 View
by Zacks Equity Research
Intersect (XENT) expects the impact of the coronavirus pandemic to substantially dampen revenues in the second quarter as well.
Here's Why You Should Add ResMed (RMD) in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about ResMed (RMD) on its focus on digital health technology and combatting the coronavirus outbreak.
Here's Why You Should Retain Allscripts in Your Portfolio Now
by Zacks Equity Research
Investor confidence remains high in Allscripts' (MDRX) stock, thanks to solid prospects.
PRA Health Unit to Offer Free Access to Metys COVID-19 Module
by Zacks Equity Research
PRA Health's (PRAH) new module is likely to boost Data Solutions segment.
Bio-Rad Rides on International Expansion Amid Cost Concerns
by Zacks Equity Research
Each of Bio-Rad's (BIO) key segments registers solid growth across three major geographies of America, Europe and Asia.
Hologic (HOLX) Posts Q2 Preliminary Results, Withdraws View
by Zacks Equity Research
Investors remain optimistic with Hologic's (HOLX) balanced segmental preliminary revenue results for second-quarter fiscal 2020.
Here's Why You Should Add Surmodics to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high in Surmodics' (SRDX) stock,thanks to solid prospects.
SurModics (SRDX) Down 22.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
SurModics (SRDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Surmodics (SRDX) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Surmodics' (SRDX) fiscal first-quarter earnings benefit from higher revenues, segmental growth and strong fiscal 2020 outlook.
SurModics (SRDX) Surpasses Q1 Earnings Estimates
by Zacks Equity Research
SurModics (SRDX) delivered earnings and revenue surprises of 266.67% and -0.89%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: SurModics (SRDX) Q1 Earnings Expected to Decline
by Zacks Equity Research
SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: SurModics (SRDX) Q1 Earnings Expected to Decline
by Zacks Equity Research
SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.